Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 12/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008968 | 0.83 | ACACB (0.50) | ACACBNOTUMFFAR4PRMT5WDR77 | |
| SCHEMBL17392419 | 0.78 | NOTUM (0.55) | ACACBNOTUMFFAR4PRMT5WDR77 | |
| SCHEMBL17392415 | 0.78 | NOTUM (0.55) | ACACBNOTUMFFAR4PRMT5WDR77 | |
| SCHEMBL13486520 | 0.75 | NOTUM (0.50) | ACACBNOTUMFFAR4PRMT5WDR77 | |
| SCHEMBL29117227 | 0.75 | NOTUM (0.55) | ACACBNOTUMFFAR4PRMT5WDR77 | |
| SCHEMBL29117230 | 0.75 | NOTUM (0.55) | ACACBNOTUMFFAR4PRMT5WDR77 | |
| SCHEMBL20009019 | 0.75 | PRMT5 (0.46) | ACACBNOTUMFFAR4PRMT5WDR77 | |
| SCHEMBL12209951 | 0.74 | FFAR4 (0.56) | ACACBNOTUMFFAR4PRMT5WDR77 | |
| SCHEMBL19119238 | 0.73 | CHRM1 (0.44) | ACACB | |
| SCHEMBL30555283 | 0.73 | USP2 (0.50) | ACACBNOTUMFFAR4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126927-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | ACACB 931/4885NOTUM 1393/4885FFAR4 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.